CL2004000677A1 - Compuestos derivados de piperidinas; procedimiento de preparacion; composicion farmaceutica; utiles como moduladores de la actividad del receptor de quimioquina en el tratamiento de enfermedades autoinmunes, inflamatorias, proliferativas o mediadas i - Google Patents

Compuestos derivados de piperidinas; procedimiento de preparacion; composicion farmaceutica; utiles como moduladores de la actividad del receptor de quimioquina en el tratamiento de enfermedades autoinmunes, inflamatorias, proliferativas o mediadas i

Info

Publication number: CL2004000677A1
Authority: CL; Chile
Prior art keywords: chemioquine; piperidins; proliferative; modulators; autoimmune
Prior art date: 2003-04-01

Application number

CL200400677A

Other languages

English (en)

Inventor

Moya Luckhurst Chris M Caffrey

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-01

Filing date

2004-03-30

Publication date

2005-04-22

2004-03-30 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-04-22 Publication of CL2004000677A1 publication Critical patent/CL2004000677A1/es

Links

230000001363 autoimmune Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
230000000694 effects Effects 0.000 title 1
230000002757 inflammatory effect Effects 0.000 title 1
238000000034 method Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
230000002062 proliferating effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Neurology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Virology (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)

CL200400677A 2003-04-01 2004-03-30 Compuestos derivados de piperidinas; procedimiento de preparacion; composicion farmaceutica; utiles como moduladores de la actividad del receptor de quimioquina en el tratamiento de enfermedades autoinmunes, inflamatorias, proliferativas o mediadas i CL2004000677A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE0300957A SE0300957D0 (sv)	2003-04-01	2003-04-01	Chemical compounds

Publications (1)

Publication Number	Publication Date
CL2004000677A1 true CL2004000677A1 (es)	2005-04-22

Family

ID=20290898

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200400677A CL2004000677A1 (es)	2003-04-01	2004-03-30	Compuestos derivados de piperidinas; procedimiento de preparacion; composicion farmaceutica; utiles como moduladores de la actividad del receptor de quimioquina en el tratamiento de enfermedades autoinmunes, inflamatorias, proliferativas o mediadas i

Country Status (24)

Country	Link
US (2)	US7495013B2 (es)
EP (1)	EP1620400B1 (es)
JP (1)	JP3911006B2 (es)
KR (1)	KR20050108419A (es)
CN (1)	CN100460391C (es)
AR (1)	AR043820A1 (es)
AU (1)	AU2004226010B2 (es)
BR (1)	BRPI0409069A (es)
CA (1)	CA2521073A1 (es)
CL (1)	CL2004000677A1 (es)
CO (1)	CO5611151A2 (es)
ES (1)	ES2398462T3 (es)
IS (1)	IS8089A (es)
MX (1)	MXPA05010374A (es)
MY (1)	MY135396A (es)
NO (1)	NO20055068L (es)
NZ (1)	NZ542506A (es)
RU (1)	RU2005128793A (es)
SE (1)	SE0300957D0 (es)
TW (1)	TW200505857A (es)
UA (1)	UA81014C2 (es)
UY (1)	UY28248A1 (es)
WO (1)	WO2004087659A1 (es)
ZA (1)	ZA200507943B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR033517A1 (es) *	2000-04-08	2003-12-26	Astrazeneca Ab	Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
ATE319703T1 (de)	2001-07-02	2006-03-15		Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
GB0120461D0 (en)	2001-08-22	2001-10-17	Astrazeneca Ab	Novel compounds
GB0122503D0 (en)	2001-09-18	2001-11-07	Astrazeneca Ab	Chemical compounds
AU2003209204A1 (en) *	2002-01-10	2003-07-30	University Of Washington	Hydrogels formed by non-covalent linkages
SE0200844D0 (sv)	2002-03-19	2002-03-19	Astrazeneca Ab	Chemical compounds
SE0200843D0 (sv) *	2002-03-19	2002-03-19	Astrazeneca Ab	Chemical compounds
SE0202838D0 (sv) *	2002-09-24	2002-09-24	Astrazeneca Ab	Chemical compounds
SE0301368D0 (sv) *	2003-05-09	2003-05-09	Astrazeneca Ab	Chemical compounds
SE0400925D0 (sv) *	2004-04-06	2004-04-06	Astrazeneca Ab	Chemical compounds
TW200722419A (en) *	2005-05-27	2007-06-16	Astrazeneca Ab	Chemical compounds
EP1888527A1 (en) *	2005-05-27	2008-02-20	AstraZeneca AB	Piperidines for the treatment of chemokine mediated diseases
JP2009501793A (ja)	2005-07-21	2009-01-22	アストラゼネカ・アクチエボラーグ	新規ピペリジン誘導体
WO2009151910A2 (en) *	2008-05-25	2009-12-17	Wyeth	Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1250719A (es)	1969-03-19	1971-10-20
US4505915A (en)	1979-05-29	1985-03-19	Merck & Co., Inc.	6-N-Heterocyclyl penicillins
US4556660A (en)	1982-07-12	1985-12-03	Janssen Pharmaceutica N.V.	N-(Bicyclic heterocyclyl)-4-piperidinamines
DK139684A (da)	1983-04-11	1984-10-12	Janssen Pharmaceutica Nv	N-aryl-alpha-amino-carboxamider
US4634704A (en)	1983-10-06	1987-01-06	Janssen Pharmaceutica, N.V.	Anti-allergic five membered heterocyclic ring containing N-(bicyclic heterocycyl)-4-piperidinamines
US4588722A (en)	1984-01-09	1986-05-13	Janssen Pharmaceutica N.V.	N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
PH23995A (en)	1984-01-09	1990-02-09	Janssen Pharmaceutica Nv	4((bicycle heterocyclyl)-methyl and hetero)piperidines
US4695575A (en)	1984-11-13	1987-09-22	Janssen Pharmaceutica, N.V.	4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
TW221996B (es)	1991-11-14	1994-04-01	Glaxo Group Ltd
GB9319534D0 (en)	1993-09-22	1993-11-10	Boots Co Plc	Therapeutic agents
US5889006A (en)	1995-02-23	1999-03-30	Schering Corporation	Muscarinic antagonists
IL117149A0 (en)	1995-02-23	1996-06-18	Schering Corp	Muscarinic antagonists
US5696267A (en)	1995-05-02	1997-12-09	Schering Corporation	Substituted oximes, hydrazones and olefins as neurokinin antagonists
AU5966096A (en)	1995-06-09	1997-01-09	Eli Lilly And Company	Methods of treating cold and allergic rhinitis
TW531537B (en)	1995-12-27	2003-05-11	Janssen Pharmaceutica Nv	1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
ES2182104T3 (es)	1996-07-10	2003-03-01	Schering Corp	Piperidinas 1,4-disustituidas como antagonistas muscarinicos.
US5952349A (en)	1996-07-10	1999-09-14	Schering Corporation	Muscarinic antagonists for treating memory loss
EP0821954A1 (en)	1996-08-01	1998-02-04	Eli Lilly And Company	Method for treating mental retardation
US5977138A (en)	1996-08-15	1999-11-02	Schering Corporation	Ether muscarinic antagonists
JP3390179B2 (ja)	1996-08-15	2003-03-24	シェーリングコーポレイション	エーテルムスカリン様アンタゴニスト
SK285631B6 (sk)	1996-09-10	2007-05-03	Dr. Karl Thomae Gmbh	Modifikované aminokyseliny, farmaceutický prostriedok s ich obsahom a ich použitie
CA2296314A1 (en)	1997-07-25	1999-02-04	Merck & Co., Inc.	Cyclic amine modulators of chemokine receptor activity
TR200002182T2 (tr)	1998-01-27	2000-12-21	Aventis Pharmaceuticals Products Inc.	İkame edilmiş aksozaherosayklil faktör xa inhibitörleri
JP2002501898A (ja)	1998-02-02	2002-01-22	メルクエンドカムパニーインコーポレーテッド	ケモカイン受容体活性の環状アミン調節剤
TWI245763B (en)	1998-04-02	2005-12-21	Janssen Pharmaceutica Nv	Biocidal benzylbiphenyl derivatives
CA2329777A1 (en)	1998-04-27	1999-11-04	Dashyant Dhanak	Ccr-3 receptor antagonists
WO1999055674A1 (en)	1998-04-28	1999-11-04	Dainippon Pharmaceutical Co., Ltd.	1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
US6066636A (en)	1998-06-30	2000-05-23	Schering Corporation	Muscarinic antagonists
EP1091956B1 (en)	1998-06-30	2004-08-04	Schering Corporation	Muscarinic antagonists
GB9919776D0 (en)	1998-08-31	1999-10-27	Zeneca Ltd	Compoujnds
JP2003529531A (ja)	1998-11-25	2003-10-07	アヴェンティスファーマシューティカルズインコーポレイテッド	置換オキソアザへテロシクリルＸａ因子阻害剤
US6331545B1 (en)	1998-12-18	2001-12-18	Soo S. Ko	Heterocycyclic piperidines as modulators of chemokine receptor activity
KR100439357B1 (ko)	1999-05-04	2004-07-07	쉐링 코포레이션	Ｃｃｒ５ 길항제로서 유용한 피페리딘 유도체
US6387930B1 (en)	1999-05-04	2002-05-14	Schering Corporation	Piperidine derivatives useful as CCR5 antagonists
SE9902551D0 (sv)	1999-07-02	1999-07-02	Astra Pharma Prod	Novel compounds
CN1420882A (zh)	1999-07-28	2003-05-28	阿温蒂斯药物公司	取代的氧代氮杂杂环基化合物
US6294554B1 (en)	1999-09-22	2001-09-25	Schering Corporation	Muscarinic antagonists
IT1307809B1 (it)	1999-10-21	2001-11-19	Menarini Ricerche Spa	Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono.
JP2001122784A (ja) *	1999-10-27	2001-05-08	Dainippon Pharmaceut Co Ltd	１−［（１−置換−４−ピペリジニル）メチル］−４−ピペリジン誘導体からなる医薬
AR033517A1 (es)	2000-04-08	2003-12-26	Astrazeneca Ab	Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en)	2000-05-31	2000-07-19	Astrazeneca Ab	Chemical compounds
AU2001280187A1 (en)	2000-08-28	2002-03-13	Toray Industries, Inc.	Cyclic amine derivatives
GB0021670D0 (en)	2000-09-04	2000-10-18	Astrazeneca Ab	Chemical compounds
GB0104050D0 (en)	2001-02-19	2001-04-04	Astrazeneca Ab	Chemical compounds
GB2373186A (en)	2001-02-23	2002-09-18	Astrazeneca Ab	Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
MXPA03008356A (es)	2001-03-13	2003-12-11	Schering Corp	Compuestos del tipo no imidazol como antagonistas de histamina h3.
GB0107907D0 (en)	2001-03-29	2001-05-23	Smithkline Beecham Plc	Novel compounds
AR033452A1 (es)	2001-03-29	2003-12-17	Schering Corp	Antagonistas de ccr5 utiles para el tratamiento del sida
GB0108876D0 (en)	2001-04-09	2001-05-30	Novartis Ag	Organic Compounds
EP1389616B1 (en)	2001-04-27	2011-07-27	Mitsubishi Tanabe Pharma Corporation	3,4-Dihalobenzylpiperidine derivatives and their medical use
ATE319703T1 (de)	2001-07-02	2006-03-15		Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
GB0117899D0 (en)	2001-07-23	2001-09-12	Astrazeneca Ab	Chemical compounds
GB0120461D0 (en)	2001-08-22	2001-10-17	Astrazeneca Ab	Novel compounds
AR036366A1 (es)	2001-08-29	2004-09-01	Schering Corp	Derivados de piperidina utiles como antagonistas de ccr5, composiciones farmaceuticas, el uso de dichos derivados para la fabricación de un medicamento y un kit
JP2003081937A (ja)	2001-09-07	2003-03-19	Bayer Ag	ベンゼンスルホンアミド誘導体
GB0122503D0 (en)	2001-09-18	2001-11-07	Astrazeneca Ab	Chemical compounds
SE0200844D0 (sv)	2002-03-19	2002-03-19	Astrazeneca Ab	Chemical compounds
SE0200843D0 (sv)	2002-03-19	2002-03-19	Astrazeneca Ab	Chemical compounds
US6696468B2 (en)	2002-05-16	2004-02-24	Dainippon Pharmaceutical Co., Ltd.	(s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
SE0202838D0 (sv)	2002-09-24	2002-09-24	Astrazeneca Ab	Chemical compounds
SE0300850D0 (sv)	2003-03-25	2003-03-25	Astrazeneca Ab	Chemical compounds
SE0301368D0 (sv)	2003-05-09	2003-05-09	Astrazeneca Ab	Chemical compounds
RU2006100190A (ru)	2003-06-13	2006-08-10	Шеринг Акциенгезельшафт (De)	Производные хинолиламида в качестве антагонистов ccr-5
SE0400925D0 (sv)	2004-04-06	2004-04-06	Astrazeneca Ab	Chemical compounds
TW200722419A (en)	2005-05-27	2007-06-16	Astrazeneca Ab	Chemical compounds
EP1888527A1 (en)	2005-05-27	2008-02-20	AstraZeneca AB	Piperidines for the treatment of chemokine mediated diseases
JP2009501793A (ja)	2005-07-21	2009-01-22	アストラゼネカ・アクチエボラーグ	新規ピペリジン誘導体

2003
- 2003-04-01 SE SE0300957A patent/SE0300957D0/xx unknown
2004
- 2004-03-23 TW TW093107808A patent/TW200505857A/zh unknown
- 2004-03-30 UA UAA200508584A patent/UA81014C2/uk unknown
- 2004-03-30 MX MXPA05010374A patent/MXPA05010374A/es unknown
- 2004-03-30 BR BRPI0409069-1A patent/BRPI0409069A/pt not_active IP Right Cessation
- 2004-03-30 CL CL200400677A patent/CL2004000677A1/es unknown
- 2004-03-30 WO PCT/SE2004/000489 patent/WO2004087659A1/en not_active Ceased
- 2004-03-30 JP JP2006507992A patent/JP3911006B2/ja not_active Expired - Fee Related
- 2004-03-30 CA CA002521073A patent/CA2521073A1/en not_active Abandoned
- 2004-03-30 EP EP04724474A patent/EP1620400B1/en not_active Expired - Lifetime
- 2004-03-30 US US10/551,493 patent/US7495013B2/en not_active Expired - Fee Related
- 2004-03-30 RU RU2005128793/04A patent/RU2005128793A/ru not_active Application Discontinuation
- 2004-03-30 MY MYPI20041144A patent/MY135396A/en unknown
- 2004-03-30 KR KR1020057018585A patent/KR20050108419A/ko not_active Ceased
- 2004-03-30 UY UY28248A patent/UY28248A1/es unknown
- 2004-03-30 NZ NZ542506A patent/NZ542506A/en not_active Application Discontinuation
- 2004-03-30 ES ES04724474T patent/ES2398462T3/es not_active Expired - Lifetime
- 2004-03-30 AU AU2004226010A patent/AU2004226010B2/en not_active Ceased
- 2004-03-30 CN CNB2004800087936A patent/CN100460391C/zh not_active Expired - Fee Related
- 2004-04-01 AR ARP040101100A patent/AR043820A1/es unknown
2005
- 2005-09-28 CO CO05098396A patent/CO5611151A2/es not_active Application Discontinuation
- 2005-09-30 ZA ZA200507943A patent/ZA200507943B/xx unknown
- 2005-10-25 IS IS8089A patent/IS8089A/is unknown
- 2005-10-31 NO NO20055068A patent/NO20055068L/no not_active Application Discontinuation
2009
- 2009-01-15 US US12/354,439 patent/US20090118513A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20055068D0 (no)	2005-10-31
ES2398462T3 (es)	2013-03-19
ZA200507943B (en)	2007-04-25
MXPA05010374A (es)	2005-11-17
US20070032523A1 (en)	2007-02-08
IS8089A (is)	2005-10-25
US7495013B2 (en)	2009-02-24
US20090118513A1 (en)	2009-05-07
SE0300957D0 (sv)	2003-04-01
TW200505857A (en)	2005-02-16
UY28248A1 (es)	2004-11-08
CO5611151A2 (es)	2006-02-28
NZ542506A (en)	2008-09-26
AU2004226010A1 (en)	2004-10-14
UA81014C2 (en)	2007-11-26
EP1620400B1 (en)	2012-12-05
BRPI0409069A (pt)	2006-03-28
KR20050108419A (ko)	2005-11-16
MY135396A (en)	2008-04-30
JP3911006B2 (ja)	2007-05-09
NO20055068L (no)	2006-01-02
CN1768037A (zh)	2006-05-03
RU2005128793A (ru)	2006-05-10
AR043820A1 (es)	2005-08-17
WO2004087659A1 (en)	2004-10-14
CN100460391C (zh)	2009-02-11
CA2521073A1 (en)	2004-10-14
EP1620400A1 (en)	2006-02-01
JP2006522113A (ja)	2006-09-28
AU2004226010B2 (en)	2007-06-07

Publication	Publication Date	Title
CL2007002708A1 (es)	2008-04-04	Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
CL2007002610A1 (es)	2008-02-01	Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2008000875A1 (es)	2008-10-03	Compuestos derivados de imidazolidin-2-ona; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades tales como dislipidemia, diabetes, enfermedades inflamatorias, entre otras.
CL2007003756A1 (es)	2008-08-22	Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de proteina quinasas; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2008000670A1 (es)	2008-11-03	Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
CL2009000349A1 (es)	2010-02-19	Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CL2007002513A1 (es)	2008-04-04	Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
CL2008001994A1 (es)	2008-09-22	Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
CL2004000234A1 (es)	2005-04-15	Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CL2012003604A1 (es)	2013-03-22	Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
CL2009000697A1 (es)	2010-04-09	Compuestos derivados de 2-heteroaril-6-fenil-imidazol [1,2-a]piridinas sustituidas; moduladores de receptores not; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de cancer, inflamacion, enfermedades neurodegenerativas, psiquiatricas, epilepsia, entre otras.
CL2007002689A1 (es)	2008-04-18	Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
CL2013001654A1 (es)	2014-03-28	Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CL2007003326A1 (es)	2008-05-16	Compuestos derivados de pirrol[2,3-b]piridina, moduladores de la actividad del c-fms y/o el c-kit; composicion farmaceutica; y uso para el tratamiento de tumores de celulas mamarias, asma, artritis reumatoide, enfermedad de parkinson, entre otras.
EA200602243A1 (ru)	2007-04-27	3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
CL2008001114A1 (es)	2008-12-19	Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras.
CL2008000690A1 (es)	2008-09-12	Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
EA201001329A1 (ru)	2011-04-29	Соединения и композиции в качестве модуляторов активности gpr119
CL2007000161A1 (es)	2008-05-30	Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
EA200901032A1 (ru)	2010-02-26	Соединения и композиции в качестве модуляторов активности gpr119
EA200901166A1 (ru)	2010-04-30	Соединения и композиции в качестве модуляторов активности gpr 119
CL2008001025A1 (es)	2008-10-17	Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer.
EA200800564A1 (ru)	2008-08-29	Производные ксантина как селективные агонисты нм74а
CL2007003832A1 (es)	2008-07-25	Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades.
CL2011000119A1 (es)	2011-06-17	Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.